Zeo ScientifiX Revenue Up, But Losses Widen to $2M
Ticker: ZEOX · Form: 10-Q · Filed: Jun 16, 2025 · CIK: 1557376
Sentiment: bearish
Topics: Biotechnology, Quarterly Earnings, Net Loss, Revenue Growth, Customer Concentration, SEC Filing, 10-Q
Related Tickers: ZEOX
TL;DR
**ZEOX is burning cash faster than it's growing revenue, making it a risky bet despite sales increases.**
AI Summary
Zeo ScientifiX, Inc. reported a net loss of $1,059,600 for the three months ended April 30, 2025, a significant increase from the net loss of $673,700 for the same period in 2024. For the six months ended April 30, 2025, the net loss was $2,040,100, compared to $1,349,200 for the six months ended April 30, 2024. The company's revenue for the three months ended April 30, 2025, was $1,000,000, up from $800,000 in the prior year's comparable period, representing a 25% increase. Revenue for the six months ended April 30, 2025, was $1,900,000, an increase from $1,500,000 for the six months ended April 30, 2024, marking a 26.7% rise. A key business change is the continued reliance on a large distributor, which accounted for 70% of total revenue for the six months ended April 30, 2025, and 80% for the six months ended April 30, 2024. This customer concentration poses a significant risk, as the loss of this distributor could materially impact future revenue. The strategic outlook remains focused on increasing revenue, but the escalating net losses indicate challenges in achieving profitability despite revenue growth.
Why It Matters
Zeo ScientifiX's widening net losses, despite revenue growth, signal a critical challenge for investors regarding the company's path to profitability and operational efficiency. The heavy reliance on a single large distributor for 70% of revenue creates substantial customer concentration risk, making ZEOX highly vulnerable to changes in that relationship and potentially impacting its competitive standing against more diversified biotech firms. For employees, this financial instability could raise concerns about job security and future growth opportunities. Customers might face uncertainty regarding long-term product availability if the company's financial health deteriorates, while the broader market will watch to see if ZEOX can convert its revenue gains into sustainable earnings in the competitive biological products sector.
Risk Assessment
Risk Level: high — The risk level is high due to the significant increase in net losses, from $1,349,200 for the six months ended April 30, 2024, to $2,040,100 for the same period in 2025. This 51.2% increase in losses, despite a 26.7% revenue increase to $1,900,000, indicates deteriorating profitability. Furthermore, the company's extreme customer concentration, with one large distributor accounting for 70% of revenue for the six months ended April 30, 2025, presents a substantial business risk.
Analyst Insight
Investors should exercise extreme caution and consider divesting or avoiding ZEOX shares. The widening losses and high customer concentration suggest a precarious financial position, making it a speculative investment with significant downside potential.
Financial Highlights
- debt To Equity
- N/A
- revenue
- $1,900,000
- operating Margin
- N/A
- total Assets
- N/A
- total Debt
- N/A
- net Income
- -$2,040,100
- eps
- N/A
- gross Margin
- N/A
- cash Position
- N/A
- revenue Growth
- +26.7%
Revenue Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Large Distributor | $1,400,000 | -12.5% |
Key Numbers
- $2.04M — Net Loss (Increased from $1.35M in prior year, a 51.2% increase for the six months ended April 30, 2025.)
- $1.9M — Revenue (Increased from $1.5M in prior year, a 26.7% increase for the six months ended April 30, 2025.)
- 70% — Customer Concentration (Percentage of revenue from one large distributor for the six months ended April 30, 2025.)
- 25% — Quarterly Revenue Growth (Revenue increased from $800,000 to $1,000,000 for the three months ended April 30, 2025.)
- 51.2% — Increase in Net Loss (6 months) (Net loss grew from $1,349,200 to $2,040,100 year-over-year.)
Key Players & Entities
- Zeo ScientifiX, Inc. (company) — filer of the 10-Q
- 03 Life Sciences (company) — organization name associated with the filer
- Organicell Regenerative Medicine, Inc. (company) — former company name of Zeo ScientifiX, Inc.
- Biotech Products Services & Research, Inc. (company) — former company name of Zeo ScientifiX, Inc.
- BESPOKE TRICYCLES INC (company) — former company name of Zeo ScientifiX, Inc.
- $1,059,600 (dollar_amount) — net loss for the three months ended April 30, 2025
- $673,700 (dollar_amount) — net loss for the three months ended April 30, 2024
- $2,040,100 (dollar_amount) — net loss for the six months ended April 30, 2025
- $1,349,200 (dollar_amount) — net loss for the six months ended April 30, 2024
- $1,000,000 (dollar_amount) — revenue for the three months ended April 30, 2025
FAQ
What were Zeo ScientifiX's net losses for the most recent quarter?
Zeo ScientifiX reported a net loss of $1,059,600 for the three months ended April 30, 2025, which is an increase from the $673,700 net loss in the same period of 2024.
How much revenue did Zeo ScientifiX generate in the second quarter of 2025?
For the three months ended April 30, 2025, Zeo ScientifiX generated $1,000,000 in revenue, marking a 25% increase compared to $800,000 in the second quarter of 2024.
What is the primary risk factor for Zeo ScientifiX's revenue stream?
The primary risk factor for Zeo ScientifiX's revenue stream is customer concentration, with one large distributor accounting for 70% of total revenue for the six months ended April 30, 2025.
Did Zeo ScientifiX's net loss increase or decrease year-over-year for the six-month period?
Zeo ScientifiX's net loss increased significantly year-over-year for the six-month period, rising from $1,349,200 for the six months ended April 30, 2024, to $2,040,100 for the same period in 2025.
What was the revenue growth percentage for Zeo ScientifiX for the six months ended April 30, 2025?
Zeo ScientifiX experienced a 26.7% revenue growth for the six months ended April 30, 2025, with revenue increasing from $1,500,000 in the prior year to $1,900,000.
What is the significance of the 70% customer concentration for Zeo ScientifiX?
The 70% customer concentration means that a substantial majority of Zeo ScientifiX's revenue depends on a single large distributor, making the company highly vulnerable to any changes in that relationship or the distributor's business.
What was Zeo ScientifiX's previous company name before Organicell Regenerative Medicine, Inc.?
Before Organicell Regenerative Medicine, Inc., Zeo ScientifiX, Inc. was formerly known as Biotech Products Services & Research, Inc., with a name change date of 2015-09-17.
How does Zeo ScientifiX's financial performance impact investors?
Zeo ScientifiX's widening net losses, despite revenue growth, indicate a lack of profitability and operational efficiency, which could lead to a decrease in investor confidence and stock value.
What is the fiscal year end for Zeo ScientifiX, Inc.?
The fiscal year end for Zeo ScientifiX, Inc. is October 31.
Where is Zeo ScientifiX, Inc. headquartered?
Zeo ScientifiX, Inc. is headquartered at 3321 College Avenue, Suite 246, Davie, Florida 33314.
Risk Factors
- Customer Concentration Risk [high — financial]: The company relies heavily on a single large distributor, which accounted for 70% of total revenue for the six months ended April 30, 2025. A loss of this distributor could materially impact future revenue and financial performance.
- Escalating Net Losses [high — operational]: Net losses have increased significantly, with a $2,040,100 loss for the six months ended April 30, 2025, compared to $1,349,200 in the prior year. This indicates challenges in achieving profitability despite revenue growth.
Industry Context
Zeo ScientifiX operates in the biological products sector, specifically focusing on products that are not diagnostic substances. This industry is characterized by significant research and development costs, regulatory hurdles, and the potential for rapid innovation. Companies in this space often face challenges in scaling production and achieving market penetration.
Regulatory Implications
As a company in the biological products sector, Zeo ScientifiX is subject to stringent regulations from bodies like the FDA. Compliance with manufacturing standards, product approvals, and marketing regulations is critical. Any failure to adhere to these regulations could result in fines, product recalls, or suspension of operations.
What Investors Should Do
- Monitor distributor relationship closely.
- Analyze cost structure and path to profitability.
- Evaluate diversification strategies.
Key Dates
- 2025-04-30: End of Second Quarter and Six-Month Period — Reporting period for the 10-Q, showing increased net losses and revenue growth.
- 2025-06-16: Filing Date of 10-Q — Indicates the company is up-to-date with its SEC filings.
Glossary
- 10-Q
- A quarterly report required by the U.S. Securities and Exchange Commission (SEC) that provides a comprehensive update on a company's financial performance. (This document provides the detailed financial information and disclosures for Zeo ScientifiX, Inc.)
- Net Loss
- The amount by which a company's expenses exceed its revenues over a specific period. (Zeo ScientifiX reported a significant net loss, highlighting profitability challenges.)
- Customer Concentration Risk
- A risk that arises when a company derives a significant portion of its revenue from a small number of customers. (Zeo ScientifiX faces this risk due to its heavy reliance on a single large distributor.)
Year-Over-Year Comparison
For the six months ended April 30, 2025, Zeo ScientifiX reported revenue of $1,900,000, a 26.7% increase from $1,500,000 in the prior year. However, net losses widened significantly to $2,040,100 from $1,349,200, a 51.2% increase. The customer concentration risk remains high, with 70% of revenue coming from a single distributor, slightly down from 80% in the prior year's comparable period, but still a critical concern.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on June 16, 2025 regarding Zeo ScientifiX, Inc. (ZEOX).